结直肠癌组织中KIAA1522的表达及临床意义

doi:10.3969/j.issn.1004-616x.2017.02.002

癌变·畸变·突变 ›› 2017, Vol. 29 ›› Issue (2): 87-90,95.doi: 10.3969/j.issn.1004-616x.2017.02.002

结直肠癌组织中KIAA1522的表达及临床意义

刘婷婷¹, 梁建伟², 余竟¹, 常晨¹, 郝佳洁¹, 蔡岩¹, 周志祥², 王明荣¹, 张彤彤³, 张钰¹

1. 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院分子肿瘤学国家重点实验室, 北京 100021;
2. 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院腹部外科, 北京 100021;
3. 成都市第三人民医院实验医学研究部, 四川成都 610031

收稿日期:2016-11-23 修回日期:2017-01-12 出版日期:2017-03-31 发布日期:2017-03-31
通讯作者: 张钰,E-mail:zhangyu909@126.com;张彤彤,E-mail:163zttong@163.com E-mail:zhangyu909@126.com;163zttong@163.com
作者简介:刘婷婷,E-mail:18809883150@163.com。
基金资助:
国家自然科学基金面上项目（81472562）；国家重点研发计划项目精准医学研究专项（2016YFC0905300）

Significance in expression of KIAA1522 in colorectal cancer

LIU Tingting¹, LIANG Jianwei², YU Jing¹, CHANG Chen¹, HAO Jiajie¹, CAI Yan¹, ZHOU Zhixiang², WANG Mingrong¹, ZHANG Tongtong³, ZHANG Yu¹

1. State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021;
2. Abdominal Surgery Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021;
3. Medical Research Center, The Third People's Hospital of Chengdu, Chengdu 610031, Sichuan, China

Received:2016-11-23 Revised:2017-01-12 Online:2017-03-31 Published:2017-03-31

摘要/Abstract

摘要：

目的：检测KIAA1522蛋白在结直肠癌中的表达变化并评价其临床意义。方法：应用组织芯片-免疫组织化学染色技术，检测96例结直肠癌组织及其配对癌旁正常组织中KIAA1522蛋白的表达情况，并对其阳性表达率与结直肠癌临床病理指标及患者预后的关系进行统计学分析。结果：KIAA1522蛋白在癌旁正常结直肠上皮细胞中主要定位于细胞浆，阳性表达率为12.5%（12/96），而在结直肠癌组织中KIAA1522蛋白阳性表达率为81.3%（78/96），两者间差异显著（P < 0.05）。Kaplan-Meier生存分析结果显示，KIAA1522蛋白阳性表达与结直肠癌患者术后3年无瘤生存期短显著正相关（P=0.017，Log-rank检验）。多因素Cox回归分析结果表明，KIAA1522蛋白阳性表达是结直肠癌患者预后不良的独立预测因素（P=0.020）。卡方检验的分析结果显示，KIAA1522蛋白阳性表达与肿瘤的远处转移正相关（P=0.012，Fisher精确检验）。结论：KIAA1522在结直肠癌组织中的阳性表达与肿瘤的远处转移及患者术后生存期短显著相关，可能作为预测结直肠癌患者预后及转移的潜在分子标志。

关键词: 结直肠癌, KIAA1522, 转移, 预后

Abstract:

OBJECTIVE: To investigate expression status of KIAA1522 in colorectal cancer (CRC),and its correlation with clinicopathological features and prognosis. METHODS: Expression of KIAA1522 protein was determined with tissue microarrays-immunohistochemistry (TMA-IHC) technique in surgically-resected colorectal cancer tissues and adjacent normal epithelia from 96 patients. The relationship between KIAA1522 expression and clinicopathological characteristics and prognosis of the patients were analyzed. RESULTS: KIAA1522 protein was mainly localized in the cytoplasm of colorectal epithelial cells. While only 12.5% (12/96) of normal colorectal epithelia displayed positive staining,81.3% (78/96) of CRC specimens showed over-expression of KIAA1522. The difference between them was highly significant (P < 0.001). Kaplan-Meier survival analysis revealed that high level of KIAA1522 expression was correlated with lower 3-year disease free survival (DFS) rate of CRC patients (P=0.017). Further more,KIAA1522 up-regulation was significantly correlated with distant metastasis (P=0.012). More importantly,Cox regression analysis indicated that KIAA1522 protein expression was an independent prognosis factor in CRC (P=0.020). CONCLUSION: KIAA1522 was frequently up-regulated in CRC,and its over-expression was significantly correlated with distant metastasis and poor prognostic,thus KIAA1522 over-expression may served as a new prognostic marker in colorectal cancer.

Key words: colorectal cancer, KIAA1522, metastasis, prognosis

中图分类号:

R730.2

刘婷婷, 梁建伟, 余竟, 常晨, 郝佳洁, 蔡岩, 周志祥, 王明荣, 张彤彤, 张钰. 结直肠癌组织中KIAA1522的表达及临床意义[J]. 癌变·畸变·突变, 2017, 29(2): 87-90,95.

LIU Tingting, LIANG Jianwei, YU Jing, CHANG Chen, HAO Jiajie, CAI Yan, ZHOU Zhixiang, WANG Mingrong, ZHANG Tongtong, ZHANG Yu. Significance in expression of KIAA1522 in colorectal cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 87-90,95.

参考文献

[1] SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,2016[J]. CA Cancer J Clin,2016,66(1):7-30.

[2] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.

[3] HANAHAN D,WEINBERG R A. Hallmarks of cancer:the next generation[J]. Cell,2011,144(5):646-674.

[4] CARETHERS J M,JUNG B H. Genetics and genetic biomarkers in sporadic colorectal cancer[J]. Gastroenterology,2015,149(5):1177-1190.

[5] FREEMAN H J. Early stage colon cancer[J]. World J Gastroenterol,2013,19(46):8468-8473.

[6] OKAZAKI N K R,OHARA R. Prediction of the coding sequences of mouse homologues of KIAA gene:IV. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries[J]. DNA Res,2004,(11):205-208.

[7] 段丽琼. KIAA基因家族的研究进展[J]. 上海第二医科大学学报,2005,(4):337-340.

[8] LIU Y Z,YANG H,CAO J,et al. KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer [J]. Sci Rep,2016,6:24786.

[9] ZHANG T T,JIANG Y Y,SHANG L,et al. Overexpression of DNAJB6 promotes colorectal cancer cell invasion through an IQGAP1/ERK-dependent signaling pathway[J]. Mol Carcinog,2015,54(10):1205-1213.

[10] 吴李飞. UHRF1蛋白在结直肠癌中的表达情况及其预后判断价值[J]. 癌变·畸变·突变,2015,27(1):30-34.

[11] 张彤彤. Cortactin蛋白在结直肠癌中的表达变化及其临床意义[J]. 癌变·畸变·突变,2014,26(1):20-23.

[12] PANAGIOTOPOULOU I G,PARASHAR D,QASEM E,et al. Neoadjuvant long-course chemoradiotherapy for rectal cancer:Does time to surgery matter?[J]. Int Surg,2015,100(6):968-973.

[13] CHEN Y,YIN D,LI L,et al. Screening aberrant methylation profile in esophageal squamous cell carcinoma for Kazakhs in Xinjiang area of China[J]. Mol Biol Rep,2015,42(2):457-464.

[14] COPPEDE F. Epigenetic biomarkers of colorectal cancer:Focus on DNA methylation[J]. Cancer Lett,2014,342(2):238-247.

[15] AGELOPOULOS K,RICHTER G H,SCHMIDT E,et al. Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing sarcoma[J]. Clin Cancer Res,2015,21(21):4935-4946.

[16] LIU Y Z,JIANG Y Y,WANG B S,et al. A panel of protein markers for the early detection of lung cancer with bronchial brushing specimens[J]. Cancer Cytopathol,2014,122(11):833-841.

结直肠癌组织中KIAA1522的表达及临床意义

Significance in expression of KIAA1522 in colorectal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	郭照萌, 张华, 张鹏. Orai1对鼻咽癌细胞侵袭和上皮-间充质转化的影响及其机制[J]. 癌变·畸变·突变, 2021, 33(6): 420-425.
[3]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[4]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[5]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[6]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[7]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[8]	李博, 李改瑞, 赵伟, 彭晓琳, 赵丹, 彭绩. 用于粪便DNA检测的样本保存液制作和效果评估[J]. 癌变·畸变·突变, 2021, 33(4): 312-316.
[9]	罗娇, 张坤驰, 周莉. 三阴性乳腺癌细胞系MDA-MB-231与其脑转移细胞系中microRNA差异表达分析[J]. 癌变·畸变·突变, 2021, 33(3): 218-224.
[10]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[11]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[12]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[13]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[14]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[15]	杨修远, 潘月龙. CD10蛋白在结直肠癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 344-349.